Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 75 of 517 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/30/11
End: 12/31/11
Due: 12/31/12
Phase: N/A
Priority: Normal
Start: 06/11/20
End: 06/30/23
Due: 06/30/24
Phase: N/A
Priority: Normal
Start: 12/27/23
End: 01/25/24
Due: 01/25/25
Phase: N/A
Priority: Normal
Start: 04/03/25
End: 02/28/26
Due: 02/28/27
Phase: N/A
Priority: Normal
Start: 02/14/20
End: 01/12/23
Due: 01/12/24
Phase: N/A
Priority: Normal
Start: 10/31/11
End: 01/31/16
Due: 01/31/17
Phase: N/A
Priority: Normal
Start: 01/31/11
End: 11/30/12
Due: 11/30/13
Phase: N/A
Priority: Normal
Start: 07/15/22
End: 08/18/22
Due: 08/18/23
Phase: N/A
Priority: Normal
Start: 04/25/23
End: 09/30/25
Due: 09/30/26
Phase: N/A
Priority: Normal
Start: 02/04/21
End: 09/07/21
Due: 09/07/22
Phase: N/A
Priority: Normal
Start: 09/30/10
End: 12/31/12
Due: 12/31/13
Phase: N/A
Priority: Normal
Start: 08/23/21
End: 05/30/22
Due: 05/30/23
Phase: N/A
Priority: Normal
Start: 04/30/12
End: 10/31/14
Due: 10/31/15
Phase: N/A
Priority: Normal
Start: 03/09/17
End: 12/13/21
Due: 12/13/22
A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.
Phase: N/A
Priority: Normal
Start: 02/01/21
End: 10/15/23
Due: 10/15/24
Phase: N/A
Priority: Normal
Start: 03/18/21
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 01/22/25
End: 12/31/27
Due: 12/31/28
Phase: N/A
Priority: Normal
Start: 04/30/15
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 12/31/17
End: 12/31/19
Due: 12/31/20
Phase: N/A
Priority: Normal
Start: 01/14/24
End: 02/05/24
Due: 02/05/25
Phase: N/A
Priority: Normal
Start: 11/01/20
End: 08/01/22
Due: 08/01/23
Phase: N/A
Priority: Normal
Start: 12/31/15
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 07/14/20
End: 12/15/26
Due: 12/15/27
Phase: N/A
Priority: Normal
Start: 05/05/16
End: 06/06/18
Due: 06/06/19
Phase: N/A
Priority: Normal
Start: 12/27/21
End: 02/14/22
Due: 02/14/23